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 Materials for Drug Delivery: Innovative Solutions 
to Address Complex Biological Hurdles  1. Introduction 
 The fi eld of drug delivery focuses on 
the development of technologies to 
deliver biomolecules to the site of the 
disease so as to maximize therapeutic 
benefi ts, minimize side effects and 
enhance patient compliance. The key 
hurdle in this journey is the complexity 
of the path through which the drug has 
to navigate before arriving at the target 
site. Another hurdle is the limited avail-
ability of tools to control this navigation. 
Free drugs, when administered into 
bloodstream, are subjected to various 
metabolic processes, primarily renal 
clearance and distribution in non-target 
tissues. These processes not only reduce 
the drug concentration at the active 
target site but also increase the likeli-
hood of unwanted side effects. The best 
examples of drugs suffering from these 
limitations are chemotherapeutic agents. 
While many chemotherapeutics are 
highly effective in a petri dish in vitro, 
clinical utility of these agents is often 
limited by severe restrictions on doses 
that are posed by their toxic side effects. ©
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Adv. Mater. 2012, 24, 3717–3723These limitations can be potentially over-
come by designing carriers that perform 
multiple tasks including encapsulation 
and controlled release, minimization of 
immune-clearance, penetration of bio-
logical barriers and targeting the disease 
site. [ 1–3 ] This issue of  Advanced Materials 
is dedicated to an overview of these chal-
lenges and innovative materials that are 
being developed to address them. 
 2. Encapsulation and Release 
 The central premise of encapsulation 
of drugs in carriers is to alter their bio-
distribution or deliver combinations of 
drugs through single administration. 
Carriers can protect drugs from the 
physiological clearance mechanisms and 
thus enhance stability, while allowing 
for defi ned release profi les to be gov-
erned by designed chemistries, rather 
than biological mechanisms. Carrier 
systems have been designed to exhibit 
extended release of therapeutic drug 
doses at the target site, while decreasing 
overall systemic drug dose to levels 
below the toxicity threshold. Benefi ts of 
this strategy include higher therapeutic 
effi cacy, fewer side effects, and reduced 
number of administrations. The per-
formance of drug carriers is strongly 
related to a number of key design para-
meters including the choice of material, 
carrier architecture and their surface 
modifi cation. 
 2.1. Choice of Carrier Material 
 Polymers are one of the most com-
monly used materials for designing drug 
delivery carriers. [ 4 ] The carrier material 
needs to be compatible with the drug to 
ensure stability during synthesis, storage, 
and administration. A number of dif-
ferent strategies have been employed to  2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimcontrol the release profi les of polymeric 
delivery systems: 
 Diffusion-based Release Systems 
 In this confi guration, drugs are loaded 
into an inert polymeric matrix and the 
drug release profi le is governed by the 
diffusion of the drug through the matrix 
structure. This principle has been suc-
cessfully employed in drug-eluting 
stents, [ 5 ] and is also pursued in a number 
of particle-based delivery systems. [ 6 ] 
 Solvent-Activated Release Systems 
 Small molecule drugs and macro-
molecular drugs alike have been 
entrapped in water-swellable polymers, 
such as hydrogels. [ 6 ] Upon exposure to a 
physiological environment, the hydrogel 
hydrates, expands, and releases the incor-
porated payload. 
 Chemically Controlled Release Systems 
 If the drug carrier is made of a mate-
rial that is hydrolytically labile, the expo-
sure to a physiological environment 
can trigger degradation of the polymer 
matrix. As the polymer degrades, previ-
ously incorporated payloads are released 
exhibiting profi les that can be engineered 
through modulation of the hydrolytic sta-
bility of the carrier polymers. [ 7 ] 
 Responsive Release Systems 
 Recent research has increasingly 
focused on the development of stimulus-
responsive release systems. Specifi cally, 
biologically responsive nanoparticles 
have been at the forefront of research 
(see review by Grinstaff in this issue). 
The drug is encapsulated within a car-









L drug from the human body, even after 
administration. It is only after exposure 
to a specifi c stimulus, that the particles 
undergo a phase transition or chemical 
reaction that leads to the local release 
of the payload at a target site. Stimuli-
responsive systems can respond to 
internal or external stimuli. Internal 
stimuli include changes in the pH value, 
temperature, or the presence of specifi c 
enzymes. External stimuli include expo-
sure to light, electromagnetic waves, 
magnetic fi elds, or ultrasound. [ 7 ] An 
elegant example is provided in the form 
of plasmonic nanobubbles for delivery of 
chemotherapeutics (see paper by Lapatko 
and co-workers in this issue). 
 2.2. Carrier Architecture 
 While diffusion-based and solvent-
activated delivery systems often use 
isotropic-monolithic delivery architec-
tures, particle engineers have increas-
ingly sought after strategies that take 
advantage of fi ner control of the carrier 
architectures. [ 8 ] For instance, in case of 
polymer micelles, the drug-containing 
core is encapsulated by a polymer shell 
that ensures particle stability, provides 
opportunities for surface modifi cation, 
and controls the release profi le of the 
drug. [ 9 ] Thus, the circulation times and 
release profi les obtainable with polymer-
based micelles can substantially diverge 
from conventional micelles. The explora-
tion of increasingly complex carrier archi-
tectures becomes even more important 
since multifunctional particles are under 
development for combined imaging and 
therapeutic applications (e.g., theranos-
tics). In addition, combination therapies 
may require the release of multiple ther-
apeutics, ideally with decoupled release 
kinetics. See an article by Goodwill et al. 
in this issue for use of use of nanoparti-
cles for imaging. 
 Core–Shell Particles 
 While there are a number of different 
particle types available for drug delivery, 
micelles are by the far most widely used 
delivery systems that have been devel-
oped in a number of variations. Different wileyonlinelibrary.com ©micelle types, such as worm-like micelles, 
or silica-cored micelles can show signifi -
cant differences with respect to stability, 
effi cacy, and circulation times. [ 10 ] Among 
the most widely used synthetic systems 
are polymer micelles, circulating cap-
sules, and nanocontainers. Complex 
release kinetics can be achieved with 
hierarchically structured micelle parti-
cles, such as vesosomes. [ 11 ] In addition, 
peptide-based micelles have increasingly 
attracted a broad interest for biomedical 
applications. In this special issue, Tirrell 
and co-workers report peptide-based 
micelles that display a cytotoxic T-cell 
epitope for promotion of a protective 
immune response. 
 Polymer-Drug Conjugates 
 In polymer-drug conjugates, the drugs 
are directly bound to a carrier particle, 
which typically has a size of less than 
10 nm. Compared to the free drug, the 
carrier-bound drugs exhibit altered bio-
distribution, longer circulation times, 
and display in some cases a biologically 
responsive release trigger mechanism. [ 12 ] 
Widely used carrier systems include 
hydrophilic polymers, dendrimers, 
albumin, and noble metal nanoparti-
cles. [ 13 ] An example that uses polymer-
drug nanoparticles for two-stage release 
is provided by the so-called nanocells. [ 14 ] 
 Compartmentalized Particles 
 Combination therapy often requires 
the release of two or more drugs with 
distinct therapeutic windows. There-
fore, it would be benefi cial, at least in 
some cases, to be able to deliver two 
different drugs with fully decoupled 
release profi les. At the fi rst glance, the 
simplest solution would be the delivery 
of combinations of particles that carry 
different drugs. However, it cannot be 
ensured that the fate of two carriers in 
the body will be the same and that both 
particles will act upon a target cell at the 
same point in time. The solution to this 
fundamental dilemma may come from 
a slate of new carrier particles, so called 
multicompartmental particles, [ 15 ] where 
a single particle is comprised of different  2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimnanocontainers, or compartments, each 
being made up of distinct drug/polymer 
combinations. [ 16 ] In principle, it is even 
possible to design different release 
mechanisms into the same particle 
(see paper by Misra et al., this issue), 
or incorporate selective trigger mecha-
nisms. This type of multicompartmental 
particles is also ideally suited for com-
bined imaging and delivery applications 
(theranostics). 
 Composite and Hybrid Particles 
 A highly sophisticated example of 
nanoemulsion composite microgels is 
presented by An et al. in this issue. In 
addition, there has been an increasing 
interest in organic/inorganic hybrid 
parti cles that feature dual functionality 
for imaging and therapy. Recent trends 
in this area have been reviewed in the 
paper by Harry and Sailor in this issue. 
 2.3. Surface Modifi cation 
 Independent of the base polymers and 
the drug carrier architectures, there is 
almost always a need for surface modi-
fi cation of the carrier particles. With few 
exceptions, therapeutic nanoparticles 
injected in the body are cleared within 
minutes. [ 17–19 ] For intravenous injec-
tion of particles, the upper size limit 
for effective drug delivery is determined 
by the capillary diameter. Micron-sized 
particles have been shown to have dif-
ferent velocities, diffusion characteris-
tics and adhesion properties depending 
on the size. [ 20 ] Particles less than 200 nm 
show improved circulation half-life 
compared to larger particles. However, 
unmodifi ed nanoparticles often accumu-
late in liver and spleen within minutes 
to hours after intravenous injection. [ 21 ] 
This defeats the purpose of encapsula-
tion, since the drug is now released in 
these organs. In spite of major efforts 
during the last decades, clinical progress 
towards keeping carriers away from the 
liver and forcing them to accumulate in 
target tissues has been only moderately 
successful; certainly not living up to its 
potential to provide a “silver-bullet” for 








 The main hurdle in overcoming tar-
geting challenge is the multitude of 
biological clearance mechanisms that 
exist in the human body including the 
reticuloendothelial system (RES). From 
administration to release - typically in 
the cytosol of a cell - a series of orthog-
onal clearance mechanisms prevent 
effective and targeted delivery. A typical 
target tissue in the body, for example 
tumor, is much smaller compared to the 
liver, lungs and spleen. Further, organs 
such as liver are highly vascularized. 
Collectively, the contact time of carriers 
with the RES is much higher than that 
with the tumor. This, in combination 
with the fact that RES macrophages 
are highly effective in capturing parti-
cles, far more than tumor cells, leads to 
much higher accumulation of particles 
in the liver and spleen compared to the 
tumor. To address these hurdles, current 
strategies seek to combine particle tar-
geting via specifi c recognition of cancer 
cell biomarkers and decreased clearance 
due to “stealth” surface chemistries. A 
myriad of strategies have been developed 
to address these challenges; one at the 
time. For example, surface modifi cation 
with polyethylene glycol (PEG) is com-
monly used to reduce RES clearance [ 22 ] 
and tumor-targeting peptides to reduce 
off-site accumulation and cell-penetrating 
peptides to enhance cellular internaliza-
tion (see a review by Ruoslahti in this 
issue). Incorporation of vastly different 
features into single parti cle architecture 
has been very diffi cult, if not impossible. 
In other words, enabling drug carriers 
to bypass a cascade of clearance mecha-
nisms requires equipping the same 
particle with mutually exclusive sets of 
properties. A Multi ple-Particles-in-One 
strategy, in which different parts of the 
same parti cle can be used to address the 
diverse set of functional requirements, 
can offer a solution to this problem (in 
analogy to a Swiss army knife). However, 
technical realization of such multifunc-
tional particles has been an elusive chal-
lenge so far. The optimum surface den-
sity of binding sites vs. stealth areas will 
be one of the critical parameters, which 
will require entire novel particle architec-
tures with defi ned surface patterns ( i.e ., 
activity clusters). Adv. Mater. 2012, 24, 3717–3723 To extend the circulation time of 
drug delivery particles, the surface of 
the particles is typically covered by a 
layer of hydrogels. The most prominent 
examples include hydrophilic polymers, 
such as PEG, polysaccharides, such as 
dextran, or proteins, such as albumin, 
to minimize interactions of the par-
ticle with the immune system [ 23 ] by 
decreasing particle hydrophobicity and 
surface charge density using hydrophilic 
polymers such as PEG [ 24–26 ] and its vari-
ations. [ 27 , 28 ] This has led to the genera-
tion of several methodologies to prepare 
“stealth” nanoparticles. PEG containing 
block copolymers such as poloxam-
ines, poloxamers, PEG-PLGA have also 
been extensively studied. [ 29–32 ] Some of 
the liposome-PEG based delivery sys-
tems have also been shown to circulate 
for a couple of days. [ 33 , 34 ] Particle size 
also plays a crucial role in determining 
the fate of the injected particles. [ 28 , 35 , 36 ] 
Although these strategies have provided 
marked improvements over unmodifi ed 
particles, they have several limitations. 
Nanoparticles are still removed from cir-
culation possibly due to desorption of the 
surface coatings or activation of the com-
plement. [ 37 ] Additionally, surface modi-
fi ed particles are rapidly recognized and 
removed from circulation upon repeated 
injection. [ 37–39 ] Further, modifi cation of 
nanomaterial surface with PEG com-
promises the ability to include targeting 
moieties on the particle surface. 
 In the past few years, there has been 
a paradigm shift in developing ways to 
fi ght the immune clearance. The new 
strategies take an “active” approach 
towards evading the immune system. 
Unlike the conventional approach of 
using hydrophilic polymers to minimize 
the interactions with the immune system, 
the new strategies aim at mastering “com-
munication” with the immune system. 
For example, researchers have begun 
exploring the use of CD47, a ubiquitous 
self-marker as a means of disguising 
exogenous particles. [ 40 ] Other innovative 
approaches such as engineering par-
ticle shape [ 41 , 42 ] and mechanical prop-
erties [ 18 , 43 ] have also been developed. 
Particles with certain shapes have been 
shown to exhibit reduced macrophage 
uptake and enhanced circulation times © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimand higher targeting to the diseased 
tissue. [ 36 ] Flexibility of nanoparticles has 
also been shown to dramatically enhance 
circulation times and targeted accumula-
tion. [ 18 , 43 ] Nanoparticles have also been 
shown to hitchhike on red blood cells [ 44 ] 
which leads to enhanced circulation. In 
another approach, nanoparticles have 
been encapsulated in autologous red 
blood cells to prolong the circulation. [ 45 ] 
Cloaking nanoparticle surface with red 
blood cell membrane has also been 
shown to prolong their circulation. [ 46 ] 
Additional strategies including glyco-
calyx-mimicking particles [ 47 ] and lipopro-
tein-mimicking mimicking particles [ 48 ] 
have also been explored. In yet another 
approach, researchers have developed 
strategies to optimize surface concen-
trations of PEG and targeting ligands to 
strike a balance between prolonged cir-
culation and effective tissue accumula-
tion. [ 49 ] In another example, fi lomicelles, 
worm-like polymeric micelles, have been 
shown to circulate in mouse blood for 
around a week. [ 18 ] In this issue, Discher 
et al. report the simulation studies on 
release of chemotherapeutic drugs from 
fi lomicelles. 
 3. Penetration of Biological 
Barriers 
 3.1. Transport across Skin 
and Mucosal Barriers 
 Drug carriers have to penetrate a 
variety of tissue- and cell-level barriers 
including skin and intestinal epithelium, 
mucosal tissues, endothelium, intersti-
tium and cell membranes depending on 
the port of administration and ultimate 
target. Diffusion of nanoparticles across 
these tissues is very slow due to their 
size, especially across tissues such as skin 
and mucosa. Penetration of nanoparti-
cles into skin is limited by its topmost, 
keratinized layer, the stratum corneum. 
Penetration into skin can be enhanced 
by treatment with permeabilizing agents 
such as chemicals, [ 50 ] ultrasound, [ 51 ] and 
microneedles. [ 52 ] Several reports have doc-
uments the ability of soft nanoparticles 
such as liposomes, micelles and emul-









L  Penetration of nano- and micropar-
ticles across the intestinal epithelium 
has also been extensively studied. [ 54 , 55 ] 
This transport is limited by two barriers. 
The fi rst barrier comprises the mucosal 
layer. Mucus plays an important role of 
trapping and clearance of particulates. 
Mucus forms polyvalent interactions 
with nanoparticles thus leading to their 
trapping and clearance. In order to pen-
etrate mucus, synthetic nanoparticles 
must avoid adhesion to mucin fi bers 
and be small enough to avoid signifi -
cant steric inhibition by the dense fi ber 
mesh. Nanoparticles as large as 500 nm 
have been shown to rapidly diffuse across 
human mucus after coating with poly-
ethylene glycol. [ 56 ] In this issue, Hanes 
et al. provide an overview of mucus-
penetrating particles. In another recent 
study, the dependence of various par-
ticle parameters including size, shape 
and surface chemistry on mucociliary 
response was studied ex vivo. [ 57 ] No sig-
nifi cant differences in mucociliary clear-
ance were found between particles of 
different size and shapes. The second 
barrier comprises the monolayer of the 
epithelial cells whose tight junctions offer 
a particularly strong barrier for entry of 
nanoparticles. Nanoparticles comprising 
various materials have been synthesized 
and used to deliver macromolecules, par-
ticularly insulin and vaccines. Pathways 
of nanoparticle transport have also been 
studied. [ 58 ] 
 3.2. Transport in the Interstitium 
 Tissue interstitium is a highly hetero-
geneous and structurally complex 
medium through which nanoparticles 
have to diffuse in order to reach the target 
cell membranes. [ 59 ] The tumor interstitial 
matrix consists of a highly interconnected 
network of collagen fi bers that interact 
with other molecules, such as prote-
oglycans and glycosaminoglycans. [ 60 , 61 ] 
Transport of nanoparticles into tumors is 
further limited by the elevated interstitial 
pressure within the tumor. The primary 
mechanism of nanoparticle transport 
into interstitium is thus, diffusion. 
Diffusion of nanoparticles within the 
tumor depends on their size, charge and 0 wileyonlinelibrary.comconfi guration as well as the physicochem-
ical properties of the interstitial matrix. [ 62 ] 
Small molecules diffuse fairly rapidly in 
the tumor interstitial matrix. However, 
the diffusion coeffi cient of nanoparticles 
and liposomes is dramatically reduced 
by high viscosity, low porosity and 
matrix interactions. Accessible volumes 
of tumors to macromolecular entities 
have been shown to range from 0.04 to 
0.17. [ 63 ] Collagenase treatment increases 
the porosity, which may in turn increase 
nanoparticle penetration. [ 64 ] Indeed, the 
extravascular space available for large 
therapeutic agents decreases with the 
size of the agents. 
 The collagen matrix of the tumor 
poses a signifi cant hurdle in nanopar-
ticle diffusion. [ 65 ] In the absence of suffi -
cient diffusion through the interstitium, 
particles that extravasate from blood ves-
sels may just localize on the periphery 
of the tumor. Particle charge may also 
play a signifi cant role. Collagen fi bers 
carry a slightly positive charge at neu-
tral pH, and hence may interact with 
negatively charged nanoparticles to form 
aggregates. [ 66 ] In vitro studies using 
tumor spheroids, supplemented by math-
ematical models, have shown that nano-
particles of 20 and 40 nm in diameter 
are able to accumulate in the interior of 
the spheroid after treatment with colla-
genase, while 100 nm particles exhibited 
poor penetration in untreated spheroids 
with minor increase in penetration with 
collagenase treatment. 
 Several innovative strategies are being 
developed to enhance nanoparticle pen-
etration into solid tissues. For example, 
peptides that exhibit enhanced tissue 
penetration have been identifi ed. [ 67 , 68 ] 
Peptides that possess a motif R/KXXR/K 
have been identifi ed to bind to neuropi-
lin-1 (NRP-1), a co-receptor for VEGF 
and lead to enhanced cellular entry. [ 69 ] 
One prominent example of such pep-
tides is iRGD (CRGDKGPD), which has 
been shown to deliver nanoparticles into 
tumors. [ 70 ] 
 Nanoparticle shape has also been 
shown to enhance interstitial transport. 
In a recent study, rod-shaped nanopar-
ticles have shown enhanced diffusion in 
tumor interstitium compared to spher-
ical particles. [ 71 ] In another example, a © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimmultistage approach has been proposed 
where nanoparticles change their size to 
facilitate transport through interstitium. [ 72 ] 
In this approach, the original 100-nm 
nanoparticles extravasate from the leaky 
regions of the tumor vasculature and 
shrink to 10 nm, thus facilitating their 
penetration into the tumor parenchyma. 
Deep penetration into target tissues 
remains a signifi cant hurdle. While a 
signifi cant focus has been given to pen-
etration into tumors, several other targets, 
in particular, brain suffer from the same 
limitation. Accordingly, new materials that 
are able to enhance penetration of nano-
particles into solid tissues are required. 
 3.3. Internalization and Intracellular 
Traffi cking within Target Cells 
 Internalization of particles by cells 
is a complex process. There are some 
established thumb rules with respect to 
parti cle internalization into cells; parti-
cles  > 1  μ m are internalized by phago-
cytosis and those between diameters of 
0.2  μ m and 1  μ m are internalized by 
endocytosis. However, recent fi ndings 
suggest that particles as large as 5  μ m can 
be endocytosed through receptor medi-
ated endocytosis. [ 73 , 74 ] The extent of inter-
nalization of particles depends on various 
parameters including surface chemistry, 
size and shape. [ 75 ] Among these, surface 
chemistry is the most studied parameter. 
Association of carriers with cell mem-
branes depends extensively on surface 
hydrophobicity and charge. Hydrophobic 
particles are known to better associate 
with cell membranes, although such 
association is non-specifi c. The same is 
also true about surface charge. Positively 
charged particles have a high affi nity 
with negatively charged cell membranes. 
In spite of their strong association with 
cell membranes, hydrophobic and posi-
tively charged parti cles are not actively 
used due to their non-specifi c association 
with cells. 
 Shape of nanoparticles has also 
been engineered to enhance intracel-
lular drug delivery. Specifi cally, needle-
shaped particles have been shown to 
enhance intracellular delivery of siRNA 








to shape-induced membrane permea-
bilization. [ 76 , 77 ] In another study, rod-
shaped nanoparticles have been shown 
to exhibit enhanced intracellular uptake 
compared to spherical particles. [ 74 ] 
Another study has shown that particle 
size and shape play an intriguing role in 
endothelial targeting, receptor mediated 
endocytic internalization and intracel-
lular traffi cking. [ 36 ] Parti cle geometry 
plays an important role in therapeutic 
delivery to the endothelium. Surface 
architecture has also been shown to play 
a signifi cant role in nanoparticle uptake. 
Studies from the Stellacci group have 
shown that striated nanoparticles exhibit 
membrane penetration and delivery of 
materials in the cytoplasm [ 78 ] (also, see a 
paper by Stellacci et al. in this issue). 
 4. Accumulation at the Target 
 Targeting remains one of the key 
challenges in drug delivery. Two key 
principles are followed for targeting 
nano particles to tissues; passive targeting 
that relies on leaky vasculature and active 
targeting that uses the presence of spe-
cifi c ligands. 
 4.1. Passive Targeting: Enhanced 
Permeation and Retention 
 Tumor vasculature exhibits less organ-
ized structure and higher permeability 
compared to vasculature in healthy tis-
sues. [ 79 , 80 ] Characteristics of the EPR 
effect include extensive angiogenesis, 
defective vascular architecture and 
impaired lymphatic drainage/recovery 
system of the tumors. Solid and rap-
idly growing tumors possess inadequate 
supply of nutrients and oxygen and 
hence possess extensive angiogenesis, 
resulting in a high vascular density. 
Under such conditions, blood vessels 
form in an unorganized manner and 
possess defective architecture of the 
vascular endothelium with large gaps 
in endothelium cell–cell junctions thus 
leading to high permeability. The EPR 
effect provides an opportunity for more 
selective targeting of nanoparticles to 
tumors. ©Adv. Mater. 2012, 24, 3717–3723 The ability of nanoparticles to exhibit 
EPR depends on several parameters 
including size and surface charge. As 
the primary factor, the ability of nanopar-
ticles to accumulate in tissues through 
EPR depends on the circulation time of 
nanoparticles. Most nanoparticles are 
rapidly cleared from circulation due to 
recognition by the RES. To take advan-
tage of the EPR effect, it is critical for 
the nanocarriers to evade immune sur-
veillance and circulate for a prolonged 
period. Particles smaller than 10 nm are 
fi ltered by the kidney whereas particles 
larger than 100–200 nm are captured by 
the liver. Therefore, particles within this 
range are likely to exhibit high EPR, [ 81 ] 
although micron-size particles have also 
been shown to exhibit EPR. Surface 
charge also impacts the EPR effect. Spe-
cifi cally, positively charged particles are 
rapidly cleared from circulation, thus 
limiting their ability to accumulate in 
tumors. On the other hand, neutral and 
negatively charged particles are likely 
to exhibit longer circulation and higher 
tumor accumulation. 
 Particle shape is also known to impact 
the EPR effect. Worm-shaped fl exible 
fi lomicelles have been shown to exhibit 
higher tumor accumulation due to EPR 
compared to their spherical counterpart, 
likely due to their longer circulation. [ 18 ] 
In another study, experiments with dis-
coidal particles showed that EPR-medi-
ated accumulation of particles in tumors 
exhibited dependence on shape. Specifi -
cally, discoidal-shaped particles exhibited 
higher accumulation. [82]  Particles that 
change size have also been proposed 
to enhance the EPR effect. Specifi cally, 
nanoparticles that are able to increase 
their size in response to the low extracel-
lular pH (6.4  ∼ 6.8) in a tumor area may 
be physically confi ned in the tumor due 
to aggregation-induced increase in size 
(i.e., size increase over endothelial gap 
junction) upon extravasation. In vitro 
studies have reported hydrogel nanopar-
ticles composed of pullulan acetate (PA)- 
sulfadimethoxine (SDM) that exhibit 
remarkable size change upon exposure 
to tumoral pH (pH 6.8), resulting from 
hydrophobic transition of SDM. [ 83 ] In 
some cases, it is benefi cial to tune rather 
than avoid immunity. The progress  2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimreport by Irvine and collaborators in 
this issue describes novel routes to engi-
neer synthetic particles with designable 
immunity. 
 4.2. Active Targeting 
 Targeted delivery is achieved by sur-
face functionalization of particles with 
biomolecules such as peptides, [ 84 ] 
aptamers, [ 85 ] and antibodies. [ 86 ] A number 
of tumor-specifi c antibodies and drugs 
targeting specifi c proteins and small 
molecules are undergoing both preclin-
ical and clinical trials. Researchers have 
also developed strategies to optimize sur-
face concentrations of PEG and targeting 
ligands to strike a balance between pro-
longed circulation and effective tissue 
accumulation. These include optimiza-
tion of randomly distributed PEG and 
aptamers on nanoparticle surface [ 31 ] and 
fabrication of compartmentalized parti-
cles. [ 87 , 88 ] Kokkoli et al. provide a review 
of peptide-targeted lipid nanoparticles for 
anti-cancer drug delivery in this issue. 
 Particle shape also affects the targeting 
effi ciency. Using theoretical models to 
supplement experimental data, the effect 
of shape on the transport of cells and 
carriers through the blood vessels has 
been studied. [ 89 ] Margination, fi rm adhe-
sion and internalization are important 
features of transport of carriers through 
capillaries. Particle interaction with the 
vasculature includes receptor-ligand 
interactions and non-specifi c interac-
tions such as van der Waals, electro-
static and steric interactions. A neutrally 
buoyant spherical particle moving in 
proximity to a wall can drift laterally only 
in presence of an external force whereas 
non-spherical particles exhibit more 
complex motions with tumbling and 
rolling which can be exploited to con-
trol their margination dynamics without 
any need for lateral external forces. For 
non-spherical particles, it has been 
shown that the lateral drifting velocity is 
directly related to their aspect ratio, with 
a maximum between the two extremes: 
sphere, with aspect ratio unity, and disk, 
with aspect ratio infi nity. Discoidal parti-
cles have been shown to marginate more 









L marginated more than spherical particles 
in a gravitational fi eld. [ 90 ] Such models 
provide profound fundamental under-
standing and predictive capabilities for 
carrier behavior in fl ow and will prove 
to be instrumental in effi cient design of 
carriers. 
 Strategies to improve targeting have 
typically made use of discovery and uti-
lization of new chemical ligands. How-
ever, recent studies show that other 
physical factors such as size and shape 
impact the ability of particles to target. In 
this issue, Doshi et al. describe the ability 
of platelet-mimicking particles to target, 
in vitro, surfaces that mimic damaged 
endothelium. Development of synthetic 
materials with the complex biochemical 
and physical attributes of natural cells 
may open new opportunities in medical 
therapy. Reports have been published 
on synthetic blood cells [ 91 , 92 ] and RGD-
coated nanoparticles reproducing some 
of the functions exhibited by platelets 
during aggregation. [ 93 ] In general, bio-
logical objects such as viruses, bacteria, 
and cells provide a motivating paradigm 
for designing drug carriers. This issue 
includes a review by Little et al. on this 
topic. 
 5. Summary 
 Recent literature including the pub-
lications in this issue demonstrates 
the potential of advanced materials in 
addressing unmet needs in drug delivery. 
A variety of discoveries and innovations 
have helped the design and fabrication of 
novel drug carrier systems. Collectively, 
these innovations are making a strong 
progress towards addressing the chal-
lenges in the fi eld of therapeutic delivery. 
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